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Interferon signaling plays important roles in both intestinal
homeostasis and in the host response to pathogen infection. The
extent to which bacterial pathogens inhibit this host pathway is
an understudied area of investigation. We characterized Citro-
bacter rodentium strains bearing deletions in individual type III
secretion system effector genes to determine whether this
pathogen inhibits the host type I IFN response and which effec-
tor is responsible. TheNleB effector limited host IFN- produc-
tion by inhibiting Lys63-linked ubiquitination of TNF receptor-
associated factor 3 (TRAF3). Inhibition was dependent on the
glycosyltransferase activity of NleB. GAPDH, a target of NleB
during infection, bound to TRAF3 and was required for maxi-
mal TRAF3 ubiquitination. NleB glycosyltransferase activity
inhibitedGAPDH-TRAF3 binding, resulting in reduced TRAF3
ubiquitination. Collectively, our data reveal important interplay
between GAPDH and TRAF3 and suggest a mechanism by
which the NleB effector inhibits type I IFN signaling.
Many bacterial pathogens utilize a type III secretion system
(T3SS)2 to inject virulence proteins (effectors) into host cells to
subvert various host functions (1). Characterizing the identity
and mechanism of bacterial effectors expressed by attaching/
effacing pathogens, which include enterohemorrhagic Esche-
richia coli (EHEC), enteropathogenic E. coli (EPEC), andCitro-
bacter rodentium, has been a subject of extensive research in
recent years (2). Effector subversion of host pathways regulated
by the transcription factor NF-B has been relatively well stud-
ied (3), but less attention has been given to the potential inhi-
bition of host interferon signaling, which also functions as an
important early mediator of host defense.
Virally infected cells secrete interferon to protect other cells
from subsequent infection (4). Type I IFNs (e.g. IFN- and
IFN-) bind to a common IFN-/ receptor (5), initiating a
signal transduction cascade that ultimately induces the tran-
scription of genes with promoters containing IFN-stimulated
response elements (6). Type I IFNs induce antiviral activity via
double-stranded RNA-dependent protein kinase and 2,5-oli-
goadenylate synthetase to promote viral mRNA degradation
and inhibit translation, respectively (7).
Type I IFN production is stimulated not only by viral infec-
tion but also by bacterial components, including LPS and flagel-
lin (8). LPS binding to Toll-like receptor 4 (TLR4) induces a
type I IFN response mediated by the TRIF-related adaptor
molecule and TIR-domain-containing adapter-inducing inter-
feron- adaptor proteins (9). TRIF-related adaptor molecule-
TIR-domain-containing adapter-inducing interferon- signal-
ing results in the activation of TRAF familymember-associated
NF-B activator-binding kinase (TBK1) and inducible IB
kinase (IKK (10)). Serine phosphorylation of interferon-regu-
latory factor 3 (IRF3) ismediated byTBK1/IKK to induce IRF3
dimerization and nuclear translocation (11). Phosphorylated
IRF3 (and IRF7) dimers then associatewithAP-1, high-mobility
group proteins, and NF-B to form an IFN- enhanceasome
(12).
IFNs are important for maintaining intestinal homeostasis
and for responding to pathogen infection (13). Accordingly,
pathogens have also evolved strategies to interfere with host
type I IFN signaling. For example, the anthrax lethal factor
inhibits host IFN production by cleaving MAPKK6 (14) and by
inhibiting STAT1 and ISGF3 activation (15). The deubiquiti-
nating protease activity of Yersinia YopJ blocks TLR induction
of type I IFN at the level of TAK1 activation by inhibiting
TRAF3/6 ubiquitination (16). Vaccinia virus protein K7 pre-
vents IRF3 activation by inhibiting the interaction between
DEAD box protein 3 and IKK (17). The Ebola virus VP35 pro-
tein blocks TBK1/IKK interaction with IRF3/7 (18).
A recent study found that IFN- is induced by EPEC infection
andthat theT3SSeffectorNleDboth inhibits IFN- inductionand
enhances TNF expression to promote barrier disruption (19).
However,whetherC. rodentiumT3SS effectorsmay also inhibit
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host IFN- induction is unclear. Here, we screened C. roden-
tium strains bearing deletions in individual effector genes to
determine the extent to which this pathogen might inhibit the
host IFN- response. We found that the T3SS effector NleB
limits host IFN- production by inhibiting TRAF3 Lys63-linked
ubiquitination.
Results
NleB Inhibits the Generation of a Type I IFN Response—To
determine whether C. rodentium T3SS effectors inhibit the
host type I IFN response, wemonitored the survival of a recom-
binant vesicular stomatitis virus (VSV-G) expressing GFP (20).
HeLa cells were first infected with C. rodentium strains pos-
sessing (WT) or lacking (escN) a functional T3SS for 2 h or
were instead treated with LPS for 30 min as a positive control.
HeLa cell supernatants were then removed, filtered, and
applied to Vero cells, which are highly responsive to exogenous
IFN-. After incubation for 12 h with the supernatants, the
Vero cells were infected with VSV-G/GFP for 30 h. Cells were
then fixed, and viral loads were quantified by measuring GFP
intensity.
Transferring supernatants from cells infected with C. roden-
tium escN inhibited VSV-G/GFP to levels similar to those
induced by LPS treatment. By contrast, transferring superna-
tants from cells infectedwithWTC. rodentium had no discern-
ible ability to inhibit VSV-GFP growth (Fig. 1A). These data
suggested that a T3SS effector inhibits the production of a host
factor involved in virus inhibition. We then infected HeLa cells
with C. rodentium strains lacking individual T3SS effector
genes and screened the cell supernatants for antiviral activity.
Among the 12 individual effector deletion strains screened (Fig.
1B),nleB inhibited virus replicationmost significantly (Figs. 1,
A and B), with a minor phenotype also observed for nleE.
To test the hypothesis that this phenotype was due to the
release of type I IFN from the infected HeLa cells, we used an
antibody that blocks the IFN-/ receptor. Pretreating Vero
cells with this antibody blocked the ability of HeLa cell super-
natants to inhibit virus replication (Fig. 1C). Thus, C. roden-
tium induces a host IFN- response, and the T3SS effector
NleB blocks the transduction of this response.
NleB Inhibits IFN- and RANTES Gene Transcription—We
then conducted in vitro experiments to determine the impact of
NleB on IFN- signaling pathways. TodeterminewhetherNleB
inhibits transcription of the IFN- gene, we performed quanti-
tative RT-PCR analysis of IFNB1 transcript abundance after
infection with WT, escN, or nleB C. rodentium. Although
infection with escN stimulated IFNB1 expression similar to
LPS treatment, infection with the WT did not (Fig. 2A). This
phenotype was attributable to NleB, as deleting nleB relieved
the inhibition of IFNB1 gene transcription observed with WT
C. rodentium.Weobtained similar data for the chemokine gene
RANTES (CCL5, Fig. 2B).
IRF3 is a transcription factor that binds IFN- and other
innate immune gene promoters (21). Because NleB inhibited
IFNB1 and RANTES expression, which are both direct targets
of IRF3, we tested whether IRF nuclear abundance was altered
after bacterial infection. By fractionating cell lysates after bac-
terial infection, we observed that, although WT C. rodentium
inhibited the accumulation of nuclear IRF3, infection with
escN and nleB did not (Fig. 2C). We reached similar conclu-
sions after using immunofluorescence microscopy and scoring
the number of cells with predominantly nuclear IRF3 (Fig. 2, D
and E).
NleB Reduces the Nuclear Abundance of STAT1—IFN-
stimulation results in the activation of the JAK-STAT pathway,
which has a critical role in regulating the immune response to
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FIGURE 1.NleB inhibits the generation of a type I IFN response. A, HeLa cells were infected with C. rodentium strains for 2 h or treated with LPS (100 ng/ml)
for 30min. Cell supernatants were removed, filtered, and applied to Vero cells for 12 h, whichwere then infectedwith VSV-G/GFP (multiplicity of infection5)
for 30 h. Where indicated, Vero cells were pretreated with a type I IFN receptor blocking antibody (Ab, IFNAR2) before adding culture supernatants. B,
representative images from screening multiple C. rodentium effector deletion strains. C, quantification of VSV-G/GFP intensity (arbitrary units)  IFNAR2
antibody, normalized to DAPI intensity. *, significantly different VSV-GFP intensity compared with WT infection (one-way ANOVA, n 3).
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bacterial infection. After cytokine stimulation and activation of
JAK, STATs, including STAT1, become phosphorylated and
translocate to the nucleus, where they can activate the expres-
sion of immune response genes (22). To determine whether
NleB inhibits p-STAT1 nuclear translocation, we evaluated the
relative abundance p-STAT1 in HeLa cells infected with
C. rodentium strains with or without IFN- stimulation. We
fractionated the cells to separate nuclear from cytoplasmic
components. As expected, p-STAT1 nuclear abundance signif-
icantly increased after stimulation with IFN- (Fig. 2, F andG).
p-STAT1 nuclear abundance was reduced in samples infected
withWTC. rodentium even after stimulationwith IFN- (Fig. 2,F
andG). By contrast,nleBC. rodentium failed to inhibit p-STAT1
nuclear translocation, indicating that NleB inhibits IFN--in-
duced p-STAT1 nuclear translocation (Fig. 2, F andG).
NleB Inhibits Lys63 Ubiquitination of TRAF3—TLRs are pat-
tern recognition receptors that sense microorganisms and are
critical for the host innate immune system.A subset of liganded
TLRs activates intrinsic signaling pathways to induce type I IFN
production.We found that NleB also inhibited the activation of
an IFN--dependent luciferase reporter in the presence of
poly(I:C), a synthetic double-stranded RNA used for TLR3-de-
pendent stimulation of type I IFN, in an NleB dose-dependent
manner (Fig. 3A).
Differential ubiquitination of TNF receptor (TNFR)-associ-
ated factors can selectively activate or suppress the expression
of different groups of cytokines (23). For example, TRAF3 Lys63
ubiquitination typically activates IFN responses, whereas
TRAF3 Lys48 ubiquitination mediated by TRAF6 typically
induces pro-inflammatory cytokine expression (24). Lys48-
ubiquitin linkages typically result in proteasome-mediated pro-
tein degradation, whereas Lys63-ubiquitin linkages are gener-
ally associated with regulating protein subcellular localization
and activation (24).
We then hypothesized that NleB might inhibit TRAF3 ubiq-
uitination. We transfected RAW264.7 cells with plasmids
expressing TRAF3-FLAG and with ubiquitin-HAmutants that
contain lysine only at a single position (e.g. Lys48 or Lys63). After
36 h, cells were treated with LPS (100 ng/ml, 30 min) to induce
TRAF signaling. TRAF3-FLAG was immunoprecipitated, and
these samples were immunoblotted for HA to detect ubiquitin
conjugates. As expected, LPS treatment induced significant
Lys48- and Lys63-linked TRAF3 ubiquitination (Fig. 3B). Quan-
tification of these data is shown in Fig. 3, C and D.
Performing these studies with cells that were subsequently
infected with C. rodentium strains possessing or lacking NleB
revealed the selective impact of NleB on Lys63-linked TRAF3
ubiquitination. Although Lys48-linked TRAF3 ubiquitination
did not differ among infection conditions, Lys63-linked TRAF3
ubiquitination was significantly inhibited in cells infected with
eitherWT ornleB/pnleB C. rodentium in contrast to its ubiq-
uitination after infection with nleB C. rodentium (Fig. 3,
B–D). We corroborated these data by transfecting NleB in the
absence of bacterial infection. Transfecting NleB into
RAW264.7 cells inhibited Lys63-linked but not Lys48-linked
TRAF3 ubiquitination (Fig. 3E). Overall, these data suggest that
NleB selectively inhibits Lys63-linked TRAF3 ubiquitination.
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NleB Targets GAPDH to Regulate Lys63 Ubiquitination of
TRAF3—We showed previously that NleB functions as a translo-
cated glycosyltransferase enzyme that covalently modifies host
proteinswithGlcNAc to subvert their normal functions (25). Spe-
cifically, we found that NleB disrupts TRAF2 signaling, leading to
inhibition of the pro-inflammatory NF-B pathway (25). We also
revealed that the glycolysis enzymeGAPDH functions as a co-ac-
tivator of TRAF2 activity. The modification of GAPDH with
GlcNAcbyNleBpreventsGAPDH frombinding to and activating
TRAF2, leading to a reduced NF-B response to infection (25).
To determine the extent to which the phenotypes we
observed with TRAF3 were also dependent upon GAPDH, we
first determined whether GAPDH interacts with TRAF3.
By transfecting TRAF3-FLAG, we observed that GAPDH
immunoprecipitated with TRAF3, similar to its ability to immu-
noprecipitate with TRAF2 (Fig. 4A). Co-incubation of GAPDH
with NleB almost abolished the binding of GAPDH to TRAF3, at
low concentrations of TRAF3, as shown in pulldown assays and in
ELISAs (Fig. 4,B andC), similar to our previous observationswith
GAPDH binding to TRAF2 (25). Although a20% complex for-
mation in the presence of NleB was achieved, this is contrast to
100% complex formation in the absence of NleB (Fig. 4C).
Then we investigated whether the GAPDH-TRAF3 interac-
tion is important for TRAF3 activity in response to LPS. We
transfected GAPDH siRNA targeting the GAPDH 3 UTR and
complemented these knockdown cells with two GAPDH-Myc
plasmids, either WT or a C150S GAPDH mutant (which does
not interact with TRAFs (25)). After LPS treatment, Lys63-Ub
levels on TRAF3 were significantly elevated, as expected (Fig.
4D). Complementing GAPDH knockdown cells with WT, but
not with C150S GAPDH, supported TRAF3 ubiquitination.
Co-transfecting WT NleB, but not the glycosyltransferase-de-
ficient mutant NleB(AAA) (25), significantly reduced Lys63-
linked TRAF3 ubiquitination and inhibited the association of
GAPDH with TRAF3 (Fig. 4D).
Discussion
NleB is a translocated glycosyltransferase enzyme that was
originally studied for its ability to suppress NF-B activation
(26, 27).We found previously that NleB disrupts TRAF2 signal-
ing by modifying GAPDH with GlcNAc and preventing
GAPDH from binding to and activating TRAF2 (25). The EPEC
NleB1 effector modifies arginine residues of host proteins
(N-GlcNAcylation) rather than the more typical targeting of
serine/threonine residues (O-GlcNAcylation (28, 29)). In par-
ticular, it was found that EPEC NleB1 glycosylates the death
domains of TRADD, FADD, RIPK1, and TNFR1, blocking the
assembly of the TNFR1 complex. This N-GlcNAcylation dis-
rupts TNF signaling in EPEC-infected cells, thus impacting
NF-B activation, apoptosis, and necroptosis (28, 29). A recent
paper defined numerous amino acids that are important to the
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N-GlcNAcylation of FADD by EPEC NleB1 and also used the
C. rodentium infection model to show the role of these amino
acids in virulence (30). To date, the studies that have evaluated
the arginine-GlcNAcylation of substrates by NleB orthologs
have only described a single addition site for each protein. This
modification occurs on Arg117 in FADD (29) and on Arg235 in
TRADD (28). Labeling of an arginine residue by NleB1 was also
detected for TNFR1 and RIPK1 (28). It is conceivable that some
NleB orthologs could label other substrates, includingGAPDH,
on single or multiple arginine residues, a topic we are investi-
gating in ongoing studies.
Here we observed an additional role of C. rodentium NleB
affecting type I IFN signaling by inhibiting Lys63-linked TRAF3
ubiquitination. EPEC suppresses type I IFN production using
the T3SS effector NleD (19), which we did not observe in our
screening of C. rodentium mutants. We used the VSV-G/GFP
system as the readout for type I IFN production, in which VSV
replication is very sensitive to type I IFN secreted from bacte-
rially infected cells. By contrast, Long et al. (19) measured
IFN- mRNA levels in Caco2 cells 3 h after EPEC infection.
Because the expression of innate immunity genes is dynamic,
mRNA levels assayed at a single time point might not fully
reflect type I IFN production during bacterial infection. Addi-
tionally, the activities of the EHEC, EPEC, and C. rodentium
NleB proteins may be functionally distinct (25, 28, 29).
TRAF3, a ubiquitin ligase, together with TRAF6, are
recruited by the mitochondrion adaptor mitochondrial antivi-
ral-signaling protein to activate the non-canonical IKK-related
kinase TBK1 with various adaptor proteins, including TRAF
family member-associated NF-B activator, NAP1, and NF-B
essentialmodulator. TheTBK1complex induces the phosphor-
ylation and dimerization of IRF3, which is required for IRF3
nuclear translocation. IRF3 is amaster transcriptional regulator
of type I IFN gene expression. TLR4 activation induces Lys63-
linked TRAF3 ubiquitination, which is required for IRF3
activation.
GAPDH is a stress sensor involved in many biological pro-
cesses, including immune signaling and apoptosis (31). We
showed that the interaction between GAPDH and TRAF2 is
enhanced by TNF and is required for maximal NF-B activa-
tion after TNF stimulation (25). Here we found that GAPDH
also interacts with TRAF3 and enhances TRAF3 Lys63-linked
ubiquitination. Given that TRAF family members are widely
involved in mammalian immune signaling pathways, our data
suggest that GAPDH may have an unappreciated role in regu-
lating the immune system. There are six distinct TRAFproteins
in mammals, each containing a ring finger domain (except
TRAF1), a zinc finger motif, an amino-terminal TRAF domain,
and a carboxy-terminal TRAF domain (TRAF-C). TRAF-C is
highly conserved among all TRAFs and is responsible for the
association of TRAFs with other proteins. It will be interesting
to investigate whether GAPDH interacts with other TRAFs
under different conditions.
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rosebeadswere incubatedwithGST,GST-TRAF3, FLAG-NleB, orGST-TRAF3
FLAG-NleB. Protein interactions were analyzed using immunoblotting. C,
Immulon-2 plates were coated with 1 g of His-GAPDH and overlaid with
GST-TRAF3 in the presence or absence of FLAG-NleB. Protein binding was
detected using anti-GST antibody and 1-Step Ultra TMB-ELISA solution.
Absorbance at 450 nm was measured. D, HEK-Blue hTLR4 cells were trans-
fected with the indicated plasmids and GAPDH siRNAs. After 72 h, cells were
treatedwith 200 ng/ml LPS for 40min. Cell lysates were immunoprecipitated
usingFLAGantibodyand immunoblotted for FLAG-TRAF3,HA-K63-ubiquitin,
and GAPDH-Myc.
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NleB inhibited the TRAF3 and GAPDH interaction by mod-
ifying GAPDH with GlcNAc. Other studies have shown that
EPECNleB1 glycosylates the death domains ofTRADD, FADD,
and other death domain-containing proteins (28, 29). Although
these results are able to explain NleB function in the TNF/
NF-B signaling pathway, they fail to explain the function of
NleB in the TLR4/type I IFN pathway we report here. The role
of GAPDH in T cell activation has been described recently (32).
GAPDH functions as a “switcher” of T cell activation by binding
to AU-rich elements within the 3 UTR of IFN- mRNA to
suppress the translation of IFN- (32). Therefore, selective tar-
geting of GAPDHmight provide an interesting frameworkwith
which to understand the multiple effects of NleB on immune
signaling pathways. Overall, our data suggest thatC. rodentium
NleB affects both NF-B and interferon signaling.
Experimental Procedures
VSV-GFP assay—HeLa cells (ATCC) were grown in 6-well
plates and infected with C. rodentium strains for 3 h. After
infection, the cell supernatants were collected and filtered (0.25
m). Vero cells (ATCC) were grown in 24-well plates on cov-
erslips and treated with 500 l of cell-free HeLa supernatants
for 12 h and then infected with VSV-G/GFP (multiplicity of
infection 5) for 30 h. Vero cells were fixed with 3.7% parafor-
maldehyde before processing for immunofluorescence micros-
copy. Where indicated, Vero cells were treated with IFNAR2
antibody (1.0 g/ml) before adding HeLa supernatants.
IRF3 Nuclear Translocation—HeLa cells were grown in
6-well plates and infected with C. rodentium strains when 70%
confluent for 2–7 h. LPS (100 ng/ml, 1 h) was used as a positive
control to induce IRF nuclear translocation. Nuclear extraction
was performed as described previously (33), and nuclear pro-
teins were resolved using SDS-PAGE and immunoblotted for
IRF3 (Cell Signaling Technology).
STAT1 Assays—Overnight cultures of C. rodentium were
diluted 1:10 in DMEM and grown for 3 h without shaking to an
A600 of 0.9–1.0. HeLa cells were treated with IFN- (5000
units/ml, PBL Assay Science) for 30 min to promote STAT1
phosphorylation and nuclear translocation (34). Cells were
then inoculated with 100 l of C. rodentium cultures for 3 h.
Cells were subsequently washed with PBS, and cell fraction-
ation was conducted as described (35). The concentration of
p-STAT1 in the nuclear and cytoplasmic subcellular fractions
was normalized to poly(ADP-ribose) polymerase and tubulin
abundance, respectively.
Immunoprecipitation and Immunoblotting—Raw 264.7 cells
(ATCC) were transfected, treated, and infected as indicated.
Cells were then harvested into PBS, pooled, and centrifuged at
16,200  g for 5 min. Supernatants were removed, and cells
pellets were lysed in 20mMTris-HCl (pH 8.0), 2mMEDTA, 137
mM NaCl, 1% (v/v) Nonidet P-40, and 10% (v/v) glycerol. Sam-
ples were incubated on ice for 30 min, and cell lysates were
collected by centrifugation at 7800 g for 10 min at 4 °C. Pro-
teinGDynabeads (Invitrogen)were usedwith appropriate anti-
bodies for immunoprecipitation. Western blots were imaged
using an Odyssey infrared imaging system (LI-COR).
Luciferase Assays—HEK 293T cells (ATCC) were co-trans-
fectedata ratioof10:1 (1.0gof totalDNA)witha firefly luciferase
construct driven by a consensus IFN- promoter together with a
Renilla luciferase plasmid and with NleB-HA or an HA control
plasmid. After 24 h, cells were stimulatedwith 1.0g/ml poly(I:C)
for 12 h. Cells were then lysedwith passive lysis buffer, and lysates
were analyzed by using the Dual-Luciferase kit (Promega) with
firefly fluorescence units normalized toRenilla fluorescence units.
Luciferase assays were performed in triplicate with at least three
independently transfected cell populations.
RT-PCR—cDNA was prepared from 1 g of RNA by using
the Superscript First Strand System (Invitrogen) with oligo(dT)
primer. Real-time PCR was performed in triplicate using SYBR
Green PCR Master Mix (Ambion) in a Fast 7500 sequence
detection system (Applied Biosystems). Relative transcription
levels were calculated by using the Ct method.
Ubiquitination Assays—Anti-FLAG M2 affinity resin was
washed twice with cold TBS buffer (50 mM Tris HCl (pH 7.4)
and 150 mM NaCl) and centrifuged at 8000 g for 30 s at 4 °C.
HEK-Blue hTLR4 cells (InvivoGen) were transfected and
treated with LPS. Cells were harvested and washed with cold
PBS. Cell pellets were lysed in lysis buffer (50 mM Tris HCl (pH
7.4), 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100) on ice
for 30 min and then mixed with anti-FLAG M2 affinity resin
and rotated at 4 °C overnight. Resins were centrifuged at
8000 g for 30 s at 4 °C and then washed three times with cold
TBS buffer. Eluates were immunoblotted with FLAG-TRAF3,
GAPDH-Myc, and HA-Lys63-ubiquitin.
ELISAs—Immulon-2 96-well plates (Dynatech) were coated
with 1.0 g of GAPDH and incubated at 37 °C for 1 h. Plates
were washed with 0.05% PBS-Tween and blocked in 5% (w/v)
nonfatmilk in PBS-Tween. After washing, the plates were over-
laid with different amounts of GST-TRAF3 or with GST-
TRAF3 that had been labeled with GlcNAc by NleB. After 1-h
incubation at 37 °C, primary and secondary antibodies were
added. Plates were developed with 1-Step Ultra TMB-ELISA
solution (Thermo Scientific) and then quenched with 2 M
H2SO4. Absorbance at 450 nm was measured.
Pulldown Assays—GAPDHwas immobilized on nickel-nitri-
lotriacetic acid-agarose beads (Qiagen) and then incubated
with 1.0 g of purified GST or GST-TRAF3 in the presence or
absence of FLAG-NleB for 4 h at 4 °C. Beads were centrifuged
and washed three times with 20 mM HEPES (pH 7.9), 150 mM
KCl, 0.2 mM EDTA, 0.1% Nonidet P-40, 10% glycerol, and 1.0
mM DTT. Samples were analyzed using immunoblotting.
Statistical Analyses—Immunoblotting, luciferase, and RT-PCR
assays were analyzed statistically using one-way ANOVA and
Dunn’s multiple comparisons test. Data shown are the mean 
S.E. of at least three replicates.p	0.05was considered significant.
Author Contributions—P. R. H. conceived and coordinated the
study and wrote the paper. X. G., T. H. P., L. A. F., K. C., M. P. H.,
and G. S. designed, performed, and analyzed the experiments. C. R.
and R. H. G. assisted with analysis and interpretation of data. All
authors reviewed the results and approved the final version of the
manuscript.
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